Cellectar Stock Plunges 10.78% Amid Funding Round

On June 6, 2025, Cellectar's stock experienced a significant drop of 10.78% in pre-market trading.

Cellectar Biosciences has recently entered into agreements to raise $2.5 million through the sale of common stock priced at market value under Nasdaq rules. This strategic move is aimed at enhancing the company's financial flexibility and supporting its ongoing operations and future growth.

The company has also announced that the U.S. FDA has granted Breakthrough Therapy Designation for its pipeline drug, iopofosine I 131. This designation is intended to expedite the development and review of medicines for serious or life-threatening diseases, indicating that the drug could receive a six-month priority review of its New Drug Application.